AKEBIA THERAPEUTICS INC. overview

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., April 2, 2024 CAMBRIDGE, Mass. , April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024 , as inducements material to such employee entering...

Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics? PR Newswire NEW YORK, April 1, 2024 NEW YORK , April 1, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, MNMD, ATAI, DOMA, and ITRM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AKBA:...

Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth? PR Newswire NEW YORK, March 28, 2024 NEW YORK , March 28, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, AKBA, MNMD, SOUN, and CGC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. OCGN:...

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis PR Newswire CAMBRIDGE, Mass., March 27, 2024 Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass. , March 27, 2024 /PRNewswire/ -- Akebia...

Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics? PR Newswire NEW YORK, March 26, 2024 NEW YORK , March 26, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRDF, BIOL, AKBA, ALAB, and ATOS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CRDF:...

Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo? PR Newswire NEW YORK, March 22, 2024 NEW YORK , March 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, BA, AQST, GE, and GOEV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AKBA:...

Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax? PR Newswire NEW YORK, March 21, 2024 NEW YORK , March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOUN, AQST, AKBA, KAVL, and LU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SOUN:...

Thinking about buying stock in MicroCloud Hologram, Akebia Therapeutics, Mind Medicine, Treasure Global, or Getty Images? PR Newswire NEW YORK, March 20, 2024 NEW YORK , March 20, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOLO, AKBA, MNMD, TGL, and GETY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. HOLO:...